Impact of deucravacitinib on NLR and other inflammatory biomarkers of cardiovascular risk in psoriasis: post hoc analyses of phase 3 trials

Authors

• Yi Luo, Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA. Electronic address: yi.luo@bms.com.
• Aditi B. Bal, Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA.
• Yevgeniy Balagula, Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA.
• Michael Garshick, New York University Langone Health, New York, NY 10016, USA.
• Nehal N. Mehta, The George Washington University School of Medicine and Health Sciences, Washington DC 20052, USA.

Document Type

Journal Article

Publication Date

2-24-2026

Journal

The Journal of investigative dermatology

DOI

10.1016/j.jid.2026.01.043

Keywords

Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; apremilast; high-sensitivity C-reactive protein

APA Citation

Luo, Yi; Bal, Aditi B.; Balagula, Yevgeniy; Garshick, Michael; and Mehta, Nehal N., "Impact of deucravacitinib on NLR and other inflammatory biomarkers of cardiovascular risk in psoriasis: post hoc analyses of phase 3 trials" (2026). GW Authored Works. Paper 8674.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/8674

Department

Medicine